Biopharma & Life Sciences

Inhibrx Biosciences Executive Compensation (FY25)

Name: Inhibrx Biosciences (INBX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

INBX · Executive and director compensation, fiscal 2024 to 2025

Chief executive, fiscal 2025

◇

Mark Lappe

Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on Inhibrx Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

Data as of October 22, 2026Latest filing (DEF 14A): April 23, 2026

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Inhibrx Biosciences brief$1,500Get the executive brief

Velarion Member, one year

73 figures on this page, cited to the filing that reported them. See the citations

This company is not required to report a chief executive pay ratio.

Frequently asked questions

Answers drawn from the data on this page.

Who is Inhibrx Biosciences' chief executive and what were they paid?

Mark Lappe was paid $2,892,473 in total compensation as Chief Executive Officer and Chairman of the Board of Directors for fiscal 2025. Lappe's total moved 38.5% lower from the $4,703,058 reported for fiscal 2024.

What was Inhibrx Biosciences' say-on-pay result?

As an emerging growth company, the company is exempt from the advisory say-on-pay vote.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Mark Lappe Chief Executive Officer and Chairman of the Board of Directors	◇	—	—	◇	◇	—	◇	◇
Kelly Deck Chief Financial Officer	◇	◇	—	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Mark Lappe Chief Executive Officer and Chairman of the Board of Directors	◇	◇	—	—	◇	—	◇	◇
David Matly President	◇	—	—	◇	◇	—	◇	◇
Kelly Deck Chief Financial Officer	◇	—	—	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
David Matly	OPTION	—	—	—	—	—	—	◇
Kelly Deck	OPTION	—	—	—	—	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
David Matly	Option	◇	—	◇	—
	Option	◇	—	◇	—
Mark Lappe	Option	◇	—	◇	—
Kelly Deck	Option	◇	—	◇	—
	Option	◇	—	◇	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

David Matly

President · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Equity acceleration on change in control	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Kelly Deck

Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Mark Lappe

Chief Executive Officer and Chairman of the Board of Directors · Employment agreement

Severance multiple	◇
Severance base	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Douglas G. Forsyth	◇	—	◇	—	—	—	◇
Jon Faiz Kayyem, Ph.D	◇	—	◇	—	—	—	◇
Kristiina Vuori, M.D., Ph.D	◇	—	◇	—	—	—	◇
Kimberly Manhard	◇	—	◇	—	—	—	◇

Mark P. Lappe served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.

This company is an emerging growth company and is exempt from the advisory vote on executive compensation. There is no vote to report.

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Mark Lappe (Chief Executive Officer and Chairman of the Board of Directors), FY2025 total compensation $2,892,473 (base salary $695,250) [exec_comp, SEC accession 0002007919-26-000014, filed 2026-04-23]

What this page does not include

Everything above is a fact Inhibrx Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

73 figures on this page, cited to the filing that reported them.

73 cited to the filing

Documents cited

DEF 14A, filed April 23, 2026
0002007919-26-000014
Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · OUTSTANDING EQUITY AWARDS AS OF DECEMBER 31, 2025 · and 2 more sections

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Inhibrx Biosciences executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/INBX (accessed 2026).

Short form: data: Velarion

The paid brief for Inhibrx Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/INBX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Inhibrx Biosciences executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Inhibrx Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Inhibrx Biosciences

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for Inhibrx Biosciences

Biopharma & Life Sciences rankings

Terms on this page